Tiziana Life Sciences, a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, announced that it has signed agreements with FHI Clinical and three additional providers to expedite clinical development of TZLS-501, a novel fully human anti-interleukin-6 receptor (anti-IL6R) monoclonal antibody (mAb), for the treatment of COVID-19 (SARS-CoV-2) patients.
Currently, FHI Clinical is collaborating with a team of regulatory and medical experts to help draft a protocol and drug development plan for upcoming pre-IND meetings. FHI Clinical also will provide full CRO services for the clinical study, expected to begin in Q1 2021. In this trial, TZLS-501 will be delivered as an aerosol directly to the lungs using a hand-held nebulizer.
Additional collaborators for this study include:
For more information, visit the Tiziana Life Sciences press release, and download our brochure to learn more about FHI Clinical’s COVID-19 research services.